Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model

2015 ◽  
Vol 33 (2) ◽  
pp. 159-188 ◽  
Author(s):  
Svetlana Bunimovich-Mendrazitsky ◽  
Sarel Halachmi ◽  
Natalie Kronik
Keyword(s):  
Mathematical Model ◽  
Bladder Cancer ◽  
Interleukin 2 ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy

Recurrent Sigmoid Diverticulitis After Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for Bladder Cancer

2021 ◽  
Vol 3 (2) ◽  
pp. 580-583
Author(s):  
Ayesha Kamal ◽  
Furqan Bullar ◽  
Dilhana Badurdeen ◽  
Tinsay Woreta ◽  
Venkata S. Akshintala
Keyword(s):  
Bladder Cancer ◽  
Sigmoid Diverticulitis ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy

scholarly journals A mathematical model for predicting tumor recurrence within 24 months following surgery in patients with T1 high-grade bladder cancer treated with BCG immunotherapy

Bladder ◽  
2015 ◽  
Vol 2 (2) ◽  
pp. 18 ◽  
Author(s):  
Jacob Rubinstein ◽  
Tomer Bar-On ◽  
Zaher Bahouth ◽  
Roy Mano ◽  
Ohad Shoshany ◽  
...  
Keyword(s):  
Mathematical Model ◽  
Bladder Cancer ◽  
Tumor Recurrence ◽  
High Grade ◽  
Bcg Immunotherapy

The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2

2002 ◽  
Vol 81 (3) ◽  
pp. 235-238 ◽  
Author(s):  
Carlo Magno ◽  
Darwin Melloni ◽  
Alessandro Galı̀ ◽  
Giuseppe Mucciardi ◽  
Giacomo Nicocia ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Interleukin 2 ◽  
Bacillus Calmette Guerin ◽  
Anti Tumor Activity

Polyarthritis caused by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer.

2004 ◽  
Vol 93 (5) ◽  
pp. 1000-1002 ◽  
Author(s):  
Kei Asayama ◽  
Naoki Sano ◽  
Hideyuki Murakoshi ◽  
Satoru Shibukawa ◽  
Aya Watando ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy

scholarly journals Renal Tuberculosis Following Intravesical Bacillus Calmette-Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer

2020 ◽  
Vol 74 (2) ◽  
pp. 146
Author(s):  
Senad Bajramovic ◽  
Jasmin Alic ◽  
Edna Skopljak ◽  
Adisa Chikha ◽  
Sanela Vesnic ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Renal Tuberculosis

scholarly journals Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Yuqing Liu ◽  
Jian Lu ◽  
Yi Huang ◽  
Lulin Ma
Keyword(s):  
Bladder Cancer ◽  
Adverse Reactions ◽  
Clinical Manifestations ◽  
Bacillus Calmette Guerin ◽  
Bcg Immunotherapy ◽  
Bcg Therapy ◽  
Intravesical Bcg ◽  
Proven Efficacy ◽  
Bcg Instillation ◽  
Early Establishment

Because of its proven efficacy, intravesical Bacillus Calmette-Guérin (BCG) immunotherapy is an important treatment for nonmuscle invasive bladder cancer at high risk of recurrence or progression. However, approximately 8% of patients have to stop BCG instillation as a result of its complications. Complications induced by BCG therapy can have a variety of clinical manifestations. These adverse reactions may occur in conjunction with BCG instillation or may not develop until months or years after BCG cessation. An essential step in the management complications arising from BCG is early establishment of diagnosis, particularly for distant, disseminated, and obscure infections. Therefore we reviewed the literature on the potential complications after intravesical BCG immunotherapy for bladder cancer and provide an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications.

Sign in / Sign up

Export Citation Format

Share Document